TY - JOUR
T1 - Low Grade Inflammation as a Common Pathogenetic Denominator in Age-RelatedDiseases: Novel Drug Targets for Anti-Ageing Strategies and Successful AgeingAchievement
AU - Candore, Giuseppina
AU - Caruso, Calogero
AU - Vasto, Sonya
AU - Textoris-Taube, Kathrin
AU - Esposito, Federica
AU - D'Alfonso, Sandra
AU - Franceschi, Claudio
AU - Martinelli-Boneschi, Filippo
AU - Foschini, Maria P.
AU - Scarpini, Elio
AU - Scarpini, Elio
AU - Esposito, Federica
AU - Mishto, Michele
AU - Ligorio, Claudia
AU - Cellini, Elena
AU - Galimberti, Daniela
AU - Nacmias, Benedetta
AU - Kloetzel, Peter M.
AU - Seifert, Ulrike
AU - Grimaldi, Luigi M. E.
AU - Amato, Maria Pia
AU - Giordano, Mara
AU - Fenoglio, Chiara
AU - Leone, Maurizio
AU - Bellavista, Elena
AU - Santoro, Aurelia
PY - 2010
Y1 - 2010
N2 - Nowadays, people are living much longer than they used to do, however they are not free from ageing. Ageing, an inexorableintrinsic process that affects all cells, tissues, organs and individuals, is a post-maturational process that, due to a diminished homeostasisand increased organism frailty, causes a reduction of the response to environmental stimuli and, in general, is associated to an increasedpredisposition to illness and death. However, the high incidence of death due to infectious, cardiovascular and cancer diseases underlies acommon feature in these pathologies that is represented by dysregulation of both instructive and innate immunity. Several studies showthat a low-grade systemic inflammation characterizes ageing and that inflammatory markers are significant predictors of mortality in oldhumans. This pro-inflammatory status of the elderly underlies biological mechanisms responsible for physical function decline and agerelateddiseases such as Alzheimer's disease and atherosclerosis are initiated or worsened by systemic inflammation. Understanding of theageing process should have a prominent role in new strategies for extending the health old population. Accordingly, as extensivelydiscussed in the review and in the accompanying related papers, investigating ageing pathophysiology, particularly disentangling agerelatedlow grade inflammation, is likely to provide important clues about how to develop drugs that can slow or delay ageing.
AB - Nowadays, people are living much longer than they used to do, however they are not free from ageing. Ageing, an inexorableintrinsic process that affects all cells, tissues, organs and individuals, is a post-maturational process that, due to a diminished homeostasisand increased organism frailty, causes a reduction of the response to environmental stimuli and, in general, is associated to an increasedpredisposition to illness and death. However, the high incidence of death due to infectious, cardiovascular and cancer diseases underlies acommon feature in these pathologies that is represented by dysregulation of both instructive and innate immunity. Several studies showthat a low-grade systemic inflammation characterizes ageing and that inflammatory markers are significant predictors of mortality in oldhumans. This pro-inflammatory status of the elderly underlies biological mechanisms responsible for physical function decline and agerelateddiseases such as Alzheimer's disease and atherosclerosis are initiated or worsened by systemic inflammation. Understanding of theageing process should have a prominent role in new strategies for extending the health old population. Accordingly, as extensivelydiscussed in the review and in the accompanying related papers, investigating ageing pathophysiology, particularly disentangling agerelatedlow grade inflammation, is likely to provide important clues about how to develop drugs that can slow or delay ageing.
UR - http://hdl.handle.net/10447/77295
M3 - Article
VL - 16
SP - 584
EP - 596
JO - CURRENT PHARMACEUTICAL DESIGN
JF - CURRENT PHARMACEUTICAL DESIGN
SN - 1381-6128
ER -